0.8370EUR+1.82%Mkt Cap: —P/E: —1d ago
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II cl…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value97.38M $
Revenue (TTM)7.84M $
Gross Profit-29.01M $
Net Income (TTM)-40.79M $
Revenue/Share0.0543 USD
Last Price0.8370 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees145
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINFR0005175080
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.66
EV/Revenue12.43
P/S—
P/B1.64
EPS (TTM)-0.21
EPS (Forward)—
52W Range
0.727072% of range0.8800
52W High0.8800 EUR
52W Low0.7270 EUR
Profitability
Gross Margin0.00%
Oper. Margin-684.11%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.80%
ROA-24.21%
Growth
Revenue Growth-12.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-40.27M $
CapEx (TTM)—
FCF Margin-348.38%
FCF Yield—
Net Debt-119.35M $
Net Debt/EBITDA3.25
Balance Sheet
Debt/Equity1.69
Current Ratio9.62
Quick Ratio9.55
Book Value/Sh0.4440 EUR
Cash/Share0.4080 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.62.28M
Float48.87M
Insiders80.78%
Institutions0.00%
Technical
SMA 501.584 (-47.2%)
SMA 2001.716 (-51.2%)
Beta0.68
S&P 52W Chg20.80%
Avg Vol (30d)7.49K
Avg Vol (10d)543
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—